Project Grant R01DC023937
- The National Institute on Deafness and Other Communication Disorders awarded $779,636 to Trustees of Tufts College (doing business as Tufts University School of Medicine) on February 4, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173). This project grant funds characterization and treatment development for an accelerated aging model of the olfactory epithelium using an engineered nitroreductase enzyme (OMP-NTR2.0) that mimics aged human olfactory...
- The National Institute on Deafness and Other Communication Disorders awarded Massachusetts Eye and Ear Infirmary $692,124 on July 15, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to integrate histology and translational imaging of the human cochlea. The award funds development and validation of optical coherence tomography (OCT) imaging to visualize internal cochlear structures noninvasively through the intact round window in fresh human...
- The National Institutes of Health National Institute on Deafness and Other Communication Disorders awarded Monell Chemical Senses Center $656,479 on May 1, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to investigate influenza virus-induced neuroinflammation in the olfactory sensory system and the mechanisms underlying long-term anosmia. The research tests the hypothesis that genetic deficiencies in antiviral pathways contribute to severe,...
- The National Institute on Deafness and Other Communication Disorders awarded The Medical University of South Carolina $420,118 on June 1, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to investigate transcranial focused ultrasound (TFUS) modulation of olfactory valence in the treatment of parosmia and other qualitative smell disorders. The project targets a therapeutic gap in olfactory dysfunction treatment exposed by the recent pandemic. While...
- The National Institute on Deafness and Other Communication Disorders awarded the Beckman Research Institute of the City of Hope $122,742 on May 1, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to investigate allosteric mechanisms of olfactory receptor function and develop therapeutic strategies for sensory disorders. The project, K01DC022958, will use advanced computational methods including long-timescale molecular dynamics simulations and...
- The National Institute on Deafness and Other Communication Disorders awarded the University of Virginia $1,332,370 on August 1, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to evaluate the effectiveness of olfactory training in treating post-viral olfactory loss. The project investigates olfactory training—a therapeutic intervention in which patients with olfactory dysfunction repeatedly and systematically smell odorants twice daily for three...
- The National Eye Institute of the Department of Health and Human Services awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $723,931 on August 15, 2026, under the Vision Research program (CFDA 93.867). The award funds functional characterization of lateral geniculate nucleus (LGN) microstimulation as an advanced artificial vision system. The research validates a novel 1000-channel electrode array called the Fountain Probe, engineered for volumetric...
- The National Institute on Deafness and Other Communication Disorders awarded Cold Spring Harbor Laboratory $957,448 on September 1, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to investigate the structure and logic of mitral and tufted cell projections in the olfactory system using DNA barcoding and odor response profiling. The research employs high-throughput DNA barcode sequencing-based single-cell projection mapping methods (MAPSEQ and...
- The National Institute on Deafness and Other Communication Disorders awarded the President and Fellows of Harvard College $149,636 on September 30, 2025, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to support optical coherence tomography imaging of fresh human cochlear anatomy and pathology without invading the cochlea. The award funds research to determine the natural structural anatomy of human cochleae and their functional mechanical motion in situ...
- The National Institute on Deafness and Other Communication Disorders awarded Monell Chemical Senses Center $2.654 million on March 1, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to establish a clinical research center investigating how inflammation contributes to sustained loss of taste and smell following COVID-19 infection. The award funds three integrated research projects examining the molecular mechanisms of chemosensory dysfunction....
The National Institute on Deafness and Other Communication Disorders awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $676,345 on August 3, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to develop endoscopic micro-optical coherence tomography (MOCT) and dynamic MOCT (DMOCT) imaging techniques for identifying and characterizing human olfactory epithelium in vivo. The research addresses olfactory loss, which affects approximately 10 percent of the population and significantly impacts quality of life, nutrition, and safety. Olfactory epithelium shows characteristic changes in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease prior to symptom onset, making it a candidate for early detection. Current clinical and research capabilities cannot distinguish olfactory epithelium from surrounding respiratory epithelium or identify regions of neuronal loss due to injury or age, limiting diagnostic and prognostic information for patients with smell loss and preventing accurate biopsy sampling. The project will advance previously developed intranasal MOCT probes demonstrated in awake, unsedated human subjects and recently developed DMOCT technology that acquires repeated images to reconstruct frequency signatures of intracellular motion as a proxy for metabolic activity. Early ex vivo results in mouse and human olfactory clefts show the ability to visualize olfactory epithelium morphology, including ducts and motile versus non-motile cilia. Performance occurs in Boston, Massachusetts from August 3, 2026, through July 31, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $676.3k | 8/5/26 |